Trials supported by electronic health records

Trials supported by electronic health records – a game-changer for study design and execution Professor Martin Gibson will be revealing the secrets of the successful delivery of GlaxoSmithKline’s (GSK) real world Salford Lung Study at BioData World Congress 2016 on 26 October in Cambridge. Widely recognised as the first study of its kind globally, the Salford Lung Study is a …

GSK China’s bribery scandal resolved with heavy sentence

A few months ago, GlaxoSmithKline was shamefaced with its scandal in China, involving embezzlement of public property and bribery to then deputy health commission chief, Dr. Fengping Huang. A majority of hospitals in China are state-run and are financially, minimally supported by the government. To supplement their unsatisfactory income, doctors often accept a sum to prioritize patients who require expensive …

Top 50 Pharmaceutical Companies 2014

Who are the top pharmaceutical companies in the world and what are they worth in 2014? The Pharmaceutical and Biotechnology continue to dominate the world’s R&D expenditure, with more companies in the top 10 than any other sector. This year, whilst Novartis has knocked Roche from their top spot, individual R&D spends by pharma and biotechs fail to compete with …

Pharma M&A AstraZeneca and Pfizer bid of interest

Pharma M&A Games Afoot: Pfizer is interested in AstraZeneca

AstraZeneca’s shares increased 15% on Monday morning, after US drugs giant Pfizer announced its interest in acquiring the UK company. This is the second time the company has approached AstraZeneca within a short time frame. City analyst, Andrew Baum, believed that there was now a 90% chance that Pfizer would achieve its objectives.   Pfizer approached AstraZeneca in January, with …

GSK partners with Immunocore to develop next-gen cancer drugs

Pharmaceutical giant GlaxoSmithKline has entered into a research and licensing agreement with British biotech Immunocore to develop a next-generation "beyond-antibodies" drug technology for cancer and viral diseases. It is hoped that the novel biological drugs, called ImmTACs (Immune mobilising mTCR Against Cancer), will target tumours that cannot be treated using conventional antibody-based technologies. While monoclonal T cell receptors (mTCRs) and …

eBook: Top 10 Orphan Drug Pipelines in Europe

Who has the most robust and promising pipeline of orphan medicinal products in Europe? This is the question we asked ourselves as we brought together the speaking faculty and constructed the programme for the 4th Annual World Orphan Drug Congress in Geneva. As the orphan drug market grows at an enviable rate, the pharmaceutical industry have shifted focus and investments …

GSK’s Avandia: FDA panel recommend rosiglitazone restriction relaxation

An advisory committee to the US Food and Drug Administration (FDA) has voted to recommend market restrictions on former blockbuster drug rosiglitazone in the US. The GlaxoSmithKline drug, also known as Avandia, was once of the best-selling diabetes pill in the world, but became the centre of controversy as data emerged from the RECORD study linking the drug to cardiovascular …

GSK’s drisapersen for muscular dystrophy reaches primary objective

Drisapersen, GlaxoSmithKline and Prosensa's drug for Duchenne muscular dystrophy (DMD), achieved the primary objective in a Phase II study, according to a report from Bloomberg and an abstract on the CureDuchenne website. "Today, GSK released the results of their Phase ll 24 and 48 week data", writes the CureDuchenne website. "We are very pleased to report that the results are …